Clinical Trial Update: A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 safety study of BNT331 in healthy women and in women with bacterial vaginosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Vaginosis

Drugs mentioned

• BNT331

Snippet

Sponsor: BioNTech SE | Conditions: Bacterial Vaginosis | Phase 1 | Status: COMPLETED